Staurosporine

Catalog No.S1421 Synonyms: CGP 41251

Staurosporine Chemical Structure

Molecular Weight(MW): 466.53

Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.

Size Price Stock Quantity  
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Caspase-8, 9, 3, 6, PARP, and cleaved PARP were detected in POTEG overexpressed cells and control cells with or without STS treatment.

    Mol Carcinog, 2018, 57(7):886-895. Staurosporine purchased from Selleck.

    Intracellular concentration of HSF1-phosphoserine 326, total HSF1, S6 kinase-phosphothreonine-389, total S6 kinase and β-actin, without or with heat shock in HeLa cells pretreated with mTOR inhibitors rapamycin (30 nM) and KU0063794 (2 uM) and kinase inhibitor staurosporine (100 nM) for 2 hr. Relative levels of HSF1-phosphoserine 326 in cells after the various treatments were determined by densitometric analysis of X-ray films, normalized to untreated cells (lane 1), and are indicated below the representation of the immunoblots.

    PLoS One 2012 7(6), e39679. Staurosporine purchased from Selleck.

  • J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

    J Biomol Screen 2013 18(4), 388-99. Staurosporine purchased from Selleck.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Staurosporine is a potent PKC inhibitor for PKCα, PKCγ and PKCη with IC50 of 2 nM, 5 nM and 4 nM, less potent to PKCδ (20 nM), PKCε (73 nM) and little active to PKCζ (1086 nM) in cell-free assays. Also shows inhibitory activities on other kinases, such as PKA, PKG, S6K, CaMKII, etc. Phase 3.
Targets
PKCα [1]
(Cell-free assay)
c-Fgr [2]
(Cell-free assay)
phosphorylase kinase [2]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
2 nM 2 nM 3 nM 4 nM 5 nM
In vitro

Staurosporine, a microbial alkaloid, significantly inhibits protein kinase C from rat brain with IC50 of 2.7 nM. Staurosporine displays strong inhibitory effect against HeLa S3 cells with IC50 of 4 nM. [1] Staurosporine also inhibits a variety of other protein kinases, including PKA, PKG, phosphorylase kinase, S6 kinase, Myosin light chain kinase (MLCK), CAM PKII, cdc2, v-Src, Lyn, c-Fgr, and Syk with IC50 of 15 nM, 18 nM, 3 nM, 5 nM, 21 nM, 20 nM, 9 nM, 6 nM, 20 nM, 2 nM, and 16 nM, respectively. [2] Staurosporine (1 μM) induces >90% apoptosis in PC12 cells. Consistently, Staurosporine treatment induces a rapid and prolonged elevation of intracellular free calcium levels [Ca2+]i, accumulation of mitochondrial reactive oxygen species (ROS), and subsequent mitochondrial dysfunction. [3] The apoptosis of MCF7 cells induced by Staurosporine can be enhanced by the expression of functional caspase-3 via caspase-8 activation and Bid cleavage. [4] Staurosporine treatment at 1 μM only partially inhibits IL-3-stimulated Bcl2 phosphorylation but completely blocks PKC-mediated Bcl2 phosphorylation. [5] Staurosporine induces apoptosis of human foreskin fibroblasts AG-1518, depending on the lysosomal cathepsins D mediated cytochrome c release and caspase activation. [6] In addition to activating the classical mitochondrial apoptosis pathway, Staurosporine triggers a novel intrinsic apoptosis pathway, relying on the activation of caspase-9 in the absence of Apaf-1. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human HeLa cells MYnDfZRwfG:6aXRCpIF{e2G7 MnnjOFghcA>? NInWVFhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OIUuODZizszNMi=> M2nZOFIyOzh6MUmx
human colon cancer cell line (LoVo cells) NWfVWGY{WHKxbHnm[ZJifGmxbjDhd5NigQ>? NYDkXol[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubDDsbY5mKCiOb2\vJINmdGy|KTD1d4lv\yCPVGSgZZN{[XluIFnDOVA:OC5yMEGg{txONg>? NY\jcIpROTF3OUG1NFU>
human LoVo cells M1\JcHBzd2yrZnXyZZRqd25iYYPzZZk> MWS0PEB1dyB5MjDo NVnqTo9TSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IES4JJRwKDd{IHjyd{BjgSCPVGSgZZN{[Xl? MmCzNlIyQDJ7Mkm=
P19 cells NXL4c5pNTnWwY4Tpc44h[XO|YYm= NVf0c45bUW6qaXLpeIlwdiCxZjDQcIF1\WyndD3k[ZJqfmWmIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTBwMECyJO69VS5? MX[xOVc4OTRzOR?=
human BJ cells NUW1S4s1S3m2b4TvfIlkyqCjc4PhfS=> M3[yRVczKGh? M4HEd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJLKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDDZYxk\WmwIFHNJIF{e2G7LDDJR|UxRTBwMECyJO69VS5? M4XudFIzQTJzMEix
human HT-29 cells NF64XJdHfW6ldHnvckBie3OjeR?= NY[wWnV4OiCq NYPkbYdWTW[oZXP0JI9vKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGGodHXyJFIhcHK|IIXzbY5oKEqFLUGgd5RicW6rbnegZpkh\my3b4Lld4NmdmOnIHHzd4F6 NIjuPVYzOTR{OEO3OS=>
human A549 cells MX;DfZRwfG:6aXRCpIF{e2G7 MWi3NkBp MkDXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDt[ZRpd2R? NHvieZkyQDR6NEe3OS=>
human HT-29 cells NFvEV5dHfW6ldHnvckBie3OjeR?= NXzwSoJTUW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCxdHXueIlidCCrbjDoeY1idiCKVD2yPUBk\WyuczD1d4lv\yCMQ{Gg[JlmKHO2YXnubY5oKGK7IH\seY9z\XOlZX7j[UBxdGG2ZTDy[YFl\XJiYYPzZZktKEmFNUC9Nk42KG6P M{jWTVIyPTF|Mkmz
human HT-29 cells Mn7SSpVv[3Srb36gZZN{[Xl? NWPSZZhzOiCq M3iwdWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSGStNlkh[2WubIOgZZN{\XO|ZXSgdoVlfWO2aX;uJI9nKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWgdI91\W62aXHsJIFnfGW{IEKgbJJ{KGK7IIXzbY5oKEqFMTDzeIFqdmmwZzDifUBndHWxcnXzZ4Vv[2ViY3XscE1j[XOnZDDhd5NigSxiRVO1NF0zNjZibl2u MlrINlE6PzNzMEG=
Sf9 cells MWTGeY5kfGmxbjDhd5NigQ>? M13JdGlvcGmkaYTpc44hd2ZiaIXtZY4hW3mtIHX4dJJme3OnZDDpckBU\jliY3XscJMtKEmFNUC9N{BvVS5? MUmxPFgzOzd6NB?=
human HUVEC NFywV4JRem:uaX\ldoF1cW:wIHHzd4F6 Mm\jOFghfG9iN{KgbC=> NYjFelU5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWXZGSyCjZoTldkA1QCC2bzC3NkBpenNiYomgUXRVKGG|c3H5 Mm\qNlIyQDJ7Mkm=
P19 cells M2Lqc2Z2dmO2aX;uJIF{e2G7 M1XtWGlvcGmkaYTpc44hd2ZiUILveIVqdiCNaX7hd4UhSSCrbjDQNVkh[2WubIOsJGlEPTB;NDDuUU4> NHLyOVcyPTd5MUSxPS=>
Sf9 cells MorZSpVv[3Srb36gZZN{[Xl? NF\FfXZKdmirYnn0bY9vKG:oIHj1cYFvKE[7bjDlfJBz\XO|ZXSgbY4hW2Z7IHPlcIx{KGGodHXyJFEhdWmwIHL5JGVNUVODIHnuJJBz\XOnbnPlJI9nKDFidX3vcE9NKEGWUB?= NH[w[VgyPzNzNUi1Ny=>
Sf21 cells MnfwSpVv[3Srb36gZZN{[Xl? MkXHTY5pcWKrdHnvckBw\iCMQVuzJIV5eHKnc4Pl[EBqdiCVZkKxJINmdGy|LDDJR|UxRTZibl2u NGXFd3QyPzB6OEC1PS=>
human colon carcinoma cell line HCT116 NUO2UI5GTnWwY4Tpc44h[XO|YYm= NWnHSHJ6S2:wY3XueJJifGmxbjDy[ZF2cXKnZDDmc5Ih\3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fz[2mwb33hJINmdGxibHnu[UBJS1RzMU[sJGlEPTB;NjDuUU4> MVmxOVU{PzN2NR?=
human ST486 cells M3jMbnBzd2yrZnXyZZRqd25iYYPzZZk> MnfuOFghfG9iN{KgbC=> NYfYfG0zSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWFQ5PiClZXzsd{Bi\nSncjC0PEB1dyB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxRTdibl2u MmXwNlIyQDJ7Mkm=
human MDA-MB-231 cells NHfKZnZEgXSxdH;4bYPDqGG|c3H5 M4qzO|czKGh? NEHabHREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIH3leIhw\CxiR1m1NF04NjFibl2u NI\ab28yQDR6NEe3OS=>
P19 cells MXnGeY5kfGmxbjDhd5NigQ>? NHvUfVdKdmirYnn0bY9vKG:oIFP5Z4xqdi2mZYDlcoRmdnRia3nuZZNmKDFiaX6gVFE6KGOnbHzzMEBKSzVyPUigcm0v MU[xOVc4OTRzOR?=
human DLD1 cells NWj6OIs4WHKxbHnm[ZJifGmxbjDhd5NigQ>? MVO0PE04OiCq MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESOREGgZ4VtdHNiYX\0[ZIhPDhidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME25JI5ONg>? M2TPO|IzOTh{OUK5
insect cells NHz4N5ZHfW6ldHnvckBie3OjeR?= MV;Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCrbUGg[ZhxemW|c3XkJIlvKGmwc3XjeEBk\WyuczDifUBJXFKILDDJR|UxRTFyIH7NMi=> NFzzN5kyQTF5OUC3Oi=>
V79 MZ cells M4TTWWZ2dmO2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJIFt\G:|dHXyc45mKHO7boToZZNmKGW6cILld5Nm\CCrbjDWO|khVVpiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBidGSxc4Tldo9v\SC|eX70bIV{cXNuIFnDOVA:OTFibl2u M3;lbVI1PDJ{NUG5
P19 cells NYX0OoprTnWwY4Tpc44h[XO|YYm= MXLJcohq[mm2aX;uJI9nKF[jc3P1cIFzKGWwZH;0bIVtcWGuIHfyc5d1cCCoYXP0c5IhemWlZYD0c5IhcW5iUEG5JINmdGy|LDDJR|UxRTF2IH7NMi=> NUfI[lRUOTV5N{G0NVk>
Sf9 cells MnTXSpVv[3Srb36gZZN{[Xl? M{fXblIxKG2rboO= MVnJcohq[mm2aX;uJI9nKGi3bXHuJGZ6diCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEKwJI1qdnNiYomgSWxKW0FiaX6gdJJme2WwY3Wgc4YhOSC3bX;sM2whSVSSLDDJR|UxRTF3IH7NMi=> MnrJNVc{OTV6NUO=
human PBMC NWXhS4lUTnWwY4Tpc44h[XO|YYm= MlrJNlQhcA>? M3LTdHN2eHC{ZYPzbY9vKG:oIFnMNkBxem:mdXP0bY9vKGmwIHj1cYFvKFCETVOgZYZ1\XJiMkSgbJJ{KGK7IFXMTXNCNCCLQ{WwQVE3KG6PLh?= NVfMVoxXOTh3OEWwOFY>
human A549 cells MlnuR5l1d3SxeHnjxsBie3OjeR?= NWP5eIoxPDhiaB?= NE\xUWJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhNCCLQ{WwQVIxKG6PLh?= MWGyOVgzPTl|NB?=
human CEM cells NI\ofXlEgXSxdH;4bYPDqGG|c3H5 NHPucZY4OiCq M3i5UmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4Ft[2WrbjDBUUBie3OjeTygTWM2OD1{MzDuUU4> MnfFNlI6OjFyOEG=
human HeLa cells M1uycGN6fG:2b4jpZ:Kh[XO|YYm= M1:5WlQ5KGh? M{jVSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yOUBvVS5? M1vSO|I2QDJ3OUO0
human PC3 cells NUT4dldPS3m2b4TvfIlkyqCjc4PhfS=> NV3KdnFpPDhiaB?= NVfkNVk4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZkhNCCLQ{WwQVMyKG6PLh?= M3vuSFI2QDJ3OUO0
human SF268 cells Ml7GR5l1d3SxeHnjxsBie3OjeR?= MmnBOFghcA>? NIfB[3dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6NCCJSUWwQVQ1KG6PLh?= M1jN[lIyPTF|Mkm0
human MCF7 cells M3r2ZmN6fG:2b4jpZ:Kh[XO|YYm= MUG0PEBp MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NUCgcm0v M1jldVIyOzh6MUmx
HEK293 cells MYjDfZRwfG:6aXRCpIF{e2G7 MlXUO|IhcA>? NFjhd5FEgXSxdH;4bYNqfHliYXfhbY5{fCCKRVuyPVMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSnclfsc{Bie3OjeTygTWM2OD13NjDuUU4> NXzUfWduOjR5NkOyOlI>
HUE cells NGDwV2NHfW6ldHnvckBie3OjeR?= M3rKRVkxKG2rboO= MUPJcohq[mm2aX;uJI9nKF[HR1\SNkBqdiCKVVWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB1emWjdHXkJIZweiB7MDDtbY5{KGKnZn;y[UBXTUeIIHPoZYxt\W6pZTDifUBGVEmVQTygTWM2OD15MDDuUU4> M4jxb|IxOTdyMU[z
human A431 cells M4L2ZWN6fG:2b4jpZ:Kh[XO|YYm= NWjtTJl7OjRiIHi= Ml\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{Bi\nSncjCyOEBpenNidYPpcochSW6wZYjpckBX\U[LVFOvdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1w MmXSNlI2PDFyNUG=
human Jurkat cells M{PWO3Bzd2yrZnXyZZRqd25iYYPzZZk> M13SbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgTmFMOyCneIDy[ZN{cW6pIFnMNk1{fGmvdXzheIVlKGi3bXHuJGp2emujdDDj[YxteyxiSVO1NF04OSCwTT6= NED4OmsyQTR{N{KwNy=>
HEK293 cells NXzjbHpuTnWwY4Tpc44h[XO|YYm= M3HoW2lvcGmkaYTpc44hd2ZiSVytPEBz\WynYYPlJIJ6KEiHS{K5N{Bk\WyuczDlfJBz\XO|aX7nJHBMSy2kZYThNkwhUUN3ME23O{BvVS5? M4O5flE2PzdzNEG5
human KE-97 cells MYTDfZRwfG:6aXRCpIF{e2G7 NIHNVnE4OiCq MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLSU06PyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdILlMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE{KM7:TT6= M134SVI1OzJ6Mkiz
human CHOK1 cells MmTrR5l1d3SxeHnjxsBie3OjeR?= MUG0PEBp M2fhNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNJV0tzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjF|IN88UU4> MlHVNlE2OTN{OUS=
mouse NIH/3T3 cells MlHIR5l1d3SxeHnjxsBie3OjeR?= M4fZPVk3KGh? NIDWWFlEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBPUUhxM2SzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCVUlKgZZN{[XluIFnDOVA:OC5{IN88UU4> NHzTO2ozPDN4MUWyNS=>
human A2780 cells M{S2UmN6fG:2b4jpZ:Kh[XO|YYm= M4DxcFk3KGh? NGnmWJFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u NXeybWNmOjR|NkG1NlE>
human 8505C cells NIj4[GFEgXSxdH;4bYPDqGG|c3H5 NEPjZ5c6PiCq NE\KN25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckA5PTB3QzDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvOiEQvF2u M1jFblI1OzZzNUKx
human 518A2 cells MXHDfZRwfG:6aXRCpIF{e2G7 MorEPVYhcA>? M4rjdWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJFUyQEF{IHPlcIx{KGGodHXyJFk3KGi{czDifUBUWkJiYYPzZZnwxIxiSVO1NF0xNjJizszNMi=> MV6yOFM3OTV{MR?=
human HuH7 cells Mnu1R5l1d3SxeHnjxsBie3OjeR?= NGXXO5g4OiCq NY\yUYNwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUHWKNzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|IN88UU4> MVeyOFMzQDJ6Mx?=
FL5.12-Akt1 cells NXrs[o1IWHKxbHnm[ZJifGmxbjDhd5NigQ>? M2XjbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgSmw2NjF{LVHreFEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvOjlizszNMi=> MlzLNVY1ODN4Mk[=
human MiaPaCa-2 cells NYK0c2l4WHKxbHnm[ZJifGmxbjDhd5NigQ>? MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2rYWDhR4EuOiClZXzsd{whUUN3ME2wMlM4KM7:TT6= NIPabZAyPjRzM{e4NC=>
human BGC823 cells MY\DfZRwfG:6aXRCpIF{e2G7 NYfa[o96PzJiaB?= M2jjc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeJJmNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN6IN88UU4> MoTYNlQ{Ojh{OEO=
human MCF7 cells M3T6bGN6fG:2b4jpZ:Kh[XO|YYm= MV65OkBp M{DrcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JHNTSiCjc4PhfUwhUUN3ME2wMlQh|ryPLh?= NYnId4VZOjR|NkG1NlE>
human A549 cells MXfDfZRwfG:6aXRCpIF{e2G7 MUK5OkBp NUjnU3hbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPiEQvF2u MkHnNlQ{PjF3MkG=
HEK293 cells NInoUYdEgXSxdH;4bYPDqGG|c3H5 NX6yfoxLS3m2b4TvfIlkcXS7IHHnZYlve3RiSFXLNlk{KGOnbHzzMEBGSzVyPUKg{txONg>? M2nqflI2OzF4M{G3
human Raji cells  NXPLWoZQS3m2b4TvfIlkyqCjc4PhfS=> Mn;ER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVoFrcSClZXzsd{whTUN3ME2yJO69VS5? NFv6OGgzPTNzNkOxOy=>
human HepG2 cells NVHQfnIxS3m2b4TvfIlkyqCjc4PhfS=> M3O2dWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{NCCHQ{WwQVIh|ryPLh?= MVuyOVMyPjNzNx?=
human BJ cells NH7yNVZEgXSxdH;4bYPDqGG|c3H5 NWHOVJVnS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkpiY3XscJMtKEWFNUC9NkDPxE1w MVWyOVMyPjNzNx?=
human U937 cells NU\DWZp4S3m2b4TvfIlkyqCjc4PhfS=> MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzMEBKSzVyPUKg{txONg>? NF64fGoyPzB6OEC2Oy=>

... Click to View More Cell Line Experimental Data

In vivo In the gerbil and rat ischemia models, Staurosporine pretreatment (0.1-10 ng) before ischemia prevents neuronal damage in a dose-dependent manner, suggesting the involvement of PKC in CAl pyramidal cell death after ischemia. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Enzyme assay and binding assay:

Protein kinase C is assayed in a reaction mixture (0.25 mL) containing 5 μmol of Tris/HCl, pH 7.5, 2.5 μmol of magnesium acetate, 50 μg of histone II S, 20 μg of phosphatidylserine, 0.88 μg of diolein, 125 nmol of CaCl2, 1.25 nmol of [γ-32]ATP (5-10 × 104 cpm/nmol) and 5 μg of partially purified enzyme. The binding of [3H]PDBu to protein kinase C is determined: Reaction mixture (200 μL contained 4 μmo1 of Tris/malate, pH 6.8, 20 μmol of KCl, 30 nmol of CaC12, 20 μg of phosphatidylserine, 5 μg of partially purified protein kinase C, 0.5% (final concentration) of DMSO,10 pmol of [3H]PDBu (l-3 × 104 cpm/pmol) and 10 μL of various amounts of Staurosporine.
Cell Research:

[3]

+ Expand
  • Cell lines: PC12
  • Concentrations: Dissolved in DMSO, final concentration 1 μM
  • Incubation Time: ~32 hours
  • Method:

    Cells are exposed to Staurosporine for ~32 hours. Cells are fixed in 4% paraformaldehyde and stained with the DNA-binding dye Hoechst 33342. Cells are visualized under epifluorescence illumination, and the percentage of apoptotic cells (cells with condensed and fragmented DNA) is determined.


    (Only for Reference)
Animal Research:

[8]

+ Expand
  • Animal Models: Male Mongolian gerbils or male Wistar rats subjected to transient ischemia
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~10 ng
  • Administration: Stereotaxically administered into the bilateral CAl subfield of the hippocampus
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (8.57 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 466.53
Formula

C28H26N4O3

CAS No. 62996-74-1
Storage powder
in solvent
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00082017 Terminated Lymphoma Large-Cell Ki-1|Lymphoma T-Cell National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 5 2004 Phase 2
NCT00301938 Completed Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Acute Promyelocytic Leukemia (M3)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Myelodysplastic/Myeloproliferative Neoplasms|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) December 2005 Phase 1
NCT00098956 Completed Extensive Stage Small Cell Lung Cancer|Recurrent Small Cell Lung Cancer National Cancer Institute (NCI) January 2005 Phase 2
NCT00031681 Completed Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Estrogen Receptor-negative Breast Cancer|Extensive Stage Small Cell Lung Cancer|Gastrointestinal Stromal Tumor|HER2-negative Breast Cancer|Metastatic Gastrointestinal Carcinoid Tumor|Ovarian Sarcoma|Ovarian Stromal Cancer|Progesterone Receptor-negative Breast Cancer|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor|Recurrent Breast Cancer|Recurrent Cervical Cancer|Recurrent Colon Cancer|Recurrent Endometrial Carcinoma|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Ovarian Epithelial Cancer|Recurrent Ovarian Germ Cell Tumor|Recurrent Pancreatic Cancer|Recurrent Prostate Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Cell Lung Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor|Stage IV Breast Cancer|Stage IV Colon Cancer|Stage IV Endometrial Carcinoma|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Ovarian Epithelial Cancer|Stage IV Ovarian Germ Cell Tumor|Stage IV Pancreatic Cancer|Stage IV Prostate Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer|Triple-negative Breast Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer|Unspecified Adult Solid Tumor Protocol Specific|Untreated Metastatic Squamous Neck Cancer With Occult Primary National Cancer Institute (NCI)|Washington University Siteman Cancer Center December 2001 Phase 1
NCT00012194 Terminated Unspecified Adult Solid Tumor Protocol Specific National Cancer Institute (NCI) March 2001 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products0

Tags: buy Staurosporine | Staurosporine supplier | purchase Staurosporine | Staurosporine cost | Staurosporine manufacturer | order Staurosporine | Staurosporine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID